DAPIPRAZOLE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAPIPRAZOLE HYDROCHLORIDE (DAPIPRAZOLE HYDROCHLORIDE).
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
| Metabolism | Hepatic metabolism via cytochrome P450 enzymes, primarily CYP3A4. |
| Excretion | Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%) |
| Half-life | Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment |
| Protein binding | 99% bound to albumin and alpha-1 acid glycoprotein |
| Volume of Distribution | 20-40 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 62% (first-pass metabolism) |
| Onset of Action | Oral: 1-2 hours; not available for parenteral administration |
| Duration of Action | 24 hours or longer due to long half-life; may require multiple doses for steady state |
5 mg orally once daily, titrated as needed up to 10 mg once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustment needed, but caution advised due to potential age-related renal impairment. Consider lower starting dose (2.5 mg) in frail elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DAPIPRAZOLE HYDROCHLORIDE (DAPIPRAZOLE HYDROCHLORIDE).
| Breastfeeding | Not known whether dapiprazole is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio unknown. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects observed at doses up to 10 times the maximum recommended human dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to dapiprazole or any component of the formulation.","Acute iritis or uveitis due to potential for exacerbation of inflammation or increased intraocular pressure."]
| Precautions | ["May cause transient stinging or burning on instillation.","Use with caution in patients with corneal abrasion or epithelial damage.","Patients should be advised not to drive or operate machinery until pupillary constriction is complete and vision clears."] |
| Food/Dietary | No significant food interactions. Avoid alcohol as it may increase the risk of dizziness or lightheadedness if systemic absorption occurs. |
Loading safety data…
| Monitor for maternal adverse effects including bradycardia, hypotension, and bronchospasm. Fetal monitoring via heart rate tracing with prolonged use or high doses. |
| Fertility Effects | No human data. In animal studies, no impairment of fertility observed. |
| Clinical Pearls |
| Dapiprazole is an alpha-adrenergic blocking agent used topically to reverse pharmacologically-induced mydriasis (e.g., from phenylephrine or tropicamide). Onset of action is typically within 30 minutes, with maximal effect at 1-2 hours. Do not use in patients with narrow-angle glaucoma or hypersensitivity. Monitor for conjunctival injection, burning, or ptosis. Use with caution in patients with cardiovascular disease due to potential systemic absorption. |
| Patient Advice | This medication is used to reverse pupil dilation after an eye examination. · Apply one drop into the affected eye(s) as directed by your doctor. · Wait at least 5 minutes between using this medication and any other eye drops. · You may experience temporary stinging, blurred vision, or redness after application. · Do not drive or operate machinery until your vision clears and pupils return to normal size. · Avoid touching the dropper tip to your eye or any surface to prevent contamination. · Inform your doctor if you have glaucoma, heart disease, or are taking other medications. |